

See discussions, stats, and author profiles for this publication at: <http://www.researchgate.net/publication/267507642>

# Hepatitis B Virus Genotype D is the only Genotype Circulating in Iranian chronic, the Unique pattern of Genotypic Homogeneity

ARTICLE · SEPTEMBER 2014

DOI: 10.6051/j.issn.2224-3992.2014.03.418

DOWNLOADS

80

VIEWS

90

15 AUTHORS, INCLUDING:



**Seyed Moayed Alavian**

Middle East Liver Disease Center

598 PUBLICATIONS 3,441 CITATIONS

SEE PROFILE



**Farshid Abedi**

Mashhad University of Medical Sciences

15 PUBLICATIONS 82 CITATIONS

SEE PROFILE



**Behrooz Ataei**

Isfahan University of Medical Sciences

87 PUBLICATIONS 213 CITATIONS

SEE PROFILE



**Seyed Mohamad Jazayeri**

Tehran University of Medical Sciences

57 PUBLICATIONS 253 CITATIONS

SEE PROFILE

## Hepatitis B Virus Genotype D is the Only Genotype Circulating in Iranian Chronic Carriers, the Unique Pattern of Genotypic Homogeneity

M Norouzi, F Ramezani, A Khedive, H Karimzadeh, SM Alavian, R Malekzadeh, G Montazeri, A Nejatizadeh, M Ziai, F Abedi, B Ataei, M Yaran, B Sayad, MH Somi, G Sarizade, I Sanei-Moghaddam, F Mansour-Ghanaei, H Rafatpanah, MA Pourhosseingholi, H Keyvani, S Shahmoradi, M Saberifiroozi, M Sadeghi, B Geravand, M Daram, M Mahabadi, Z Goodarzi, R Rezaee, V Poortahmasebi, Z Fakhari, SM Jazayeri

M Norouzi, F Ramezani, A Khedive, H Karimzadeh, S Shahmoradi, B Geravand<sup>1</sup>, M Daram, M Mahabadi, Z Goodarzi, R Rezaee, V Poortahmasebi, Z Fakhari, SM Jazayeri, Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran  
SM Alavian, Middle East Liver Diseases Center (MELD Centers), Tehran, Iran

R Malekzadeh, G Montazeri, Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran

A Nejatizadeh, Research Center for Molecular Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

M Ziai, Department of Internal Medicine, Vali-e-Asr Hospital, Birjand University of Medical Sciences, Birjand, Iran

F Abedi, Department of Infectious Disease, Mashhad University of Medical Sciences, Mashhad, Iran

B Ataei, M Yaran, Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

B Sayad, Kermanshah Liver Diseases and Hepatitis Research Center, Kermanshah, Iran

MH Somi, Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

G Sarizade, Educational Region of Khozestan Blood Transfusion Organization, Ahvaz, Iran

I Sanei-Moghaddam, Department of Gastroenterology, Zahedan University of Medical Sciences, Zahedan, Iran

F Mansour-Ghanaei, Gastrointestinal & Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran

H Rafatpanah, Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

MA Pourhosseingholi, Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

H Keyvani, Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

M Saberifiroozi, Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

M Sadeghi, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran

Seyed Mohammad Jazayeri, Clinical Virologist, Hepatitis B Lab-Dept Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Correspondence to: Seyed Mohammad Jazayeri, MD, PhD, Associate Professor, Clinical Virologist, Hepatitis B Lab-Dept Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, P. O. Box: 15155-6446, Iran.

Email: [jazayerism@tums.ac.ir](mailto:jazayerism@tums.ac.ir)

Telephone: +98-21-8899-2660

Fax: +98-912-715-7291

Received: April 2, 2014

Revised: July 4, 2014

Accepted: July 6, 2014

Published online: September 21, 2014

### ABSTRACT

**AIM:** To characterize the hepatitis B virus surface protein genotypes and sequence variations among HBsAg positive chronic Iranian patients from different ethnic groups.

**METHOD:** The surface genes from 312 patients were amplified and directly sequenced.

**RESULTS:** All strains (100%) belonged to genotype D and subtypes ayw2. The average nucleotide mutation frequency was 0.91 (dN/dS < 1.0), indicated negative selection. There was no significant correlation between HBV DNA and ALT levels and the occurrence of amino acid substitutions. However, in terms of HBeAg/Anti-HBe status, the association between both groups for silent nucleotide mutation was strong, indicating selection bias on missense mutations. A higher number of amino acid mutations was found in anti-HBe positive versus HBeAg positive patients.

**CONCLUSION:** The uniqueness pattern of HBV genetics homogeneity together with the low mutational frequency indicated that HBV has introduced to Iran recently and isolation of people in the absence of intermixing with other genotypes led to a homologous pattern.

© 2014 ACT. All rights reserved.

**Key words:** HBV genotype D; HBV genotypes evolution; HBV surface mutations

Norouzi M, Khedive A, Ramezani F, Karimzadeh H, Alavian SM, Malekzadeh R, Montazeri G, Nejatizadeh A, Ziai M, Abedi F, Ataci B, Yaran M, Sayad B, Somi MH, Sarizade G, Sanei-Moghaddam I, Mansour-Ghanaei F, Rafatpanah H, Pourhosseingholi MA, Keyvani H, Shahmoradi S, Saberifiroozi M, Sadeghi M, Geravand B, Daram M, Mahabadi M, Goodarzi Z, Rezaee R, Poortahmasebi V, Fakhari Z, Jazayeri SM. Hepatitis B Virus Genotype D is the Only Genotype Circulating in Iranian Chronic Carriers, the Unique Pattern of Genotypic Homogeneity. *Journal of Gastroenterology and Hepatology Research* 2014; 3(9): 1238-1243 Available from: URL: <http://www.ghrnet.org/index.php/joghr/article/view/>

## INTRODUCTION

The majority of the morbidity and mortality associated with hepatitis B is manifested in conditions, particularly cirrhosis and hepatocellular carcinoma (HCC) as complications of chronic infection. Globally, 30% of the former and 53% of the latter are attributed to hepatitis B infection, respectively<sup>[1]</sup>.

The HBV surface protein (HBsAg) changes have been classified as either "mutations" (arose after vaccine/drug therapy) or "variants" (determined by host HLA amino acid arrangement over a long period)<sup>[2]</sup>. According to the former classification, HBV mutations define a phenomenon that has been attributed to be the potential mechanism for the pathogenesis basis of chronicity and the clinical complications of this infection. Thanks to the invention of polymerase chain reaction (PCR) and other facilities for direct sequencing and other molecular approaches, hundreds of reports have been published so far to reveal the relationship between correspondent mutations and the clinical/serological pictures of the chronic patients.

Based on the above classification, HBV genome variability can usefully be classified into at least eight families (genotypes) based on sequence divergence in the entire genome of  $>8<17^{[3-6]}$ . Further, variation within a sub-component of the S gene within the major hydrophilic region (MHR) of HBsAg, the "a determinant", is strongly associated with subtype variation<sup>[7]</sup>.

Hepatitis B virus genotypes show a characteristic geographic distribution with a proposed association with human migration. Among HBV genotypes, D is the most prevalent and the most distributed genotype that has been found worldwide. It is found in Western populations, the Indian subcontinent, the Middle East and North of Africa. Genotype D contains 9 subgroups (D1 to D9), based on an intragroup divergence of less than 4% with a global distribution<sup>[8]</sup>, along with 3 subtypes (ayw2, ayw3 and ayw4). Moreover, genotype D has been reported as the only prevalent genotype infecting IV drug users in the Western World<sup>[9]</sup>.

Recent publication from different parts of Iran indicated that genotype D is the only detected HBV genotype<sup>[10-14]</sup>. In this study, we aimed to analyze the surface gene and protein in a large group of patients who were of various geographical origins and ethnic groups.

## METHODS

### Study Designs

The study population comprised of sera collected between 2006-2010. The major inclusion criterion was that a specimen should have been tested for HBsAg more than 6 months, with levels of ALT around the normal range. All patients were negative for antibodies against hepatitis C, hepatitis D and human immunodeficiency virus. To avoid bias on the mutational analysis, the patients needed to be treatment and vaccine naïve.

### Study Subjects

312 HBsAg-positive patients who were referred to the Iranian Hepatitis Network (IHN) (2006-2010), were enrolled in a cross-sectional study. To cover the whole ethnic parts of country, we studied different regions based on ethnic and geographical zones (Table 1). These patients were belonged to a cohort group whose their details of HBV molecular analysis already had been published in recent years<sup>[15-20]</sup> on the basis of individual province study in connection with IHN. The capital city, Tehran, was chosen as a versatile multi-cultural and multi-ethnic region without a definite ethnic background. Prior informed consent was obtained from all patients before bleeding. 5 mL aliquots of whole blood samples were withdrawn from each participant. Sera were separated, then transferred to Hepatitis B laboratory at Tehran University of Medical Sciences until tested. In our laboratory, HBV serological markers including HBsAg and HBeAg/anti-HBe were examined by ELISA kits manufactured by Organon Technika, Holland.

**Table 1** Origin of 312 Iranian HBsAg positive sera that were used as the source for HBsAg sequencing. The submitted sequences to GenBank are listed under accession numbers.

Ethnic group	Region	Number of samples	Accession Number
Turkish	(North-west)	17	HM348619-35 GU938342-61, 63-64
Khorasan	(North-East)	37	HQ008867-68 KC176161-72
Gilac	(North)	5	KC176137-41
Kurdish	(West)	46	HM348636-81
Fars	(South)	19	KC176142-60
Hormozgan	(South)	17	GU938305-12, 14-22
Balooch	(South-East)	21	HM348694-714
Khoozestan	(South-West)	12	HM348682-93
Isfahan	(Center)	19	GU938323-41 KC176076-99 KC176100-30
Tehran	(Center, Capital)	119	HM358277-99 HM358300-29 HM358335-39 KC176131-36
<b>Total</b>		<b>312</b>	

### DNA extraction and Polymerase Chain Reaction

HBV DNA was extracted from a 200 µL of sera using Qiagen Mini Blood Kit (Qiagen, Hilden, Germany) with a procedure adapted from the manufacturer's instructions. DNA was eluted using 100 µL of elution buffer, stored in -20°C. Surface gene including 'a' determinant antigenic domain sequences was chosen for amplification in order to determine HBV genotype/subtype and other mutations as described previously<sup>[21]</sup>.

### DNA sequencing and sequence analysis

Direct sequencing of surface genes was carried out (Perkin Elmer



which, G208C was a non-synonymous substitution that at the amino acid levels altered alanine to proline (A70P) (results not shown). We believe that this substitution was assigned as “variant” (see material and methods). According to the above mentioned description, 1,058 and 505 changes at the nucleotide and amino acid levels were true mutations, respectively (results not shown).

#### Intra-group nucleotide and amino acid substitutions in comparison with Iranian sequences

In comparison with Iranian sequences obtained from the database as well as from our unpublished data, in addition to the genotypic characterization described above, the sequences of the strains showed a few variability over the regions sequenced. In total, 205 (65.70%) out of 312 patients contained at least one amino acid mutation (Table 2). 85 (27.24%) of patients contained only silent nucleotide mutations with no subsequent amino acid alteration (Table 2). 22 (7.05%) of patients did not contain any nucleotide and amino acid substitutions at all. In all, 1,058 “nucleotide mutations” occurred, of them 505 (47.73%) were missense (amino acid altering) and 553 (52.26%) were silent (no amino acid changing). The average nucleotide mutation frequency was 3.6 events per sample. There was a probability of 0.5% for substitution per nucleotide position. Further, there were 32 non-sense nucleotide substitutions (leading to a stop codon at the amino acid level). The average amino acid mutation frequency was 1.68 mutations per sample. There was a probability of 0.74% for substitution per amino acid position. In addition, it was possible to identify the level of S proteins evolution between isolates by measuring the mutation frequency (*dN/dS*; Missense/Silent ratio) of individual sequences. The average mutation frequency of all sequences was 0.91 according to the number of mutations per site. The details of surface protein amino acid mutations distribution had been published previously elsewhere<sup>[24]</sup>.

#### Surface protein variations and clinical status

The comparison between the distribution of amino acid substitutions in the surface proteins with age, gender and ALT levels of patients showed no significant association (results not shown). Similarly, in total, there was no significant correlation between HBV DNA levels ( $<10^4$  versus  $>10^4$  copies/mL) and the occurrence of amino acid substitutions (results not shown). Nonetheless, in terms of HBeAg/Anti-HBe status, when the total number of nucleotide variations compared between both groups, the correlation was not significant ( $P$  value=0.82) (Table 2). However, the association between both groups for silent nucleotide mutation was strong ( $P$  value=0.001), indicating selection bias on missense mutations. Similarly, a higher number of amino acid mutations was found in anti-HBe positive versus HBeAg positive patients (162 vs 36,  $P$  value<0.001) (Table 2). The

relationship between both groups for “a” determinant substitutions was not significant ( $P$  value=0.67) (Table 2). Moreover, both groups did contain samples with no nucleotide and amino acid variations; however, they did not reach significant association (Table 2).

## DISCUSSION

It is important that the prevalence and types of variants of the S gene found in populations to be recorded, because this will affect policy decisions relating to vaccine and diagnostic reagents design. Therefore, in the present study, genetic variations in the whole HBeAg were analyzed comprehensively in 312 chronic patients from 9 different parts of Iran. The patient samples included in this study represent selected material from all major parts of the country with the largest sample size (in terms of HBV genotyping so far) including the main ethnic groups between Iranian populations.

Our comparison of 312 new complete surface genes and proteins with those in databases verified that genotype D and subtype ayw2 accounted for 100% of isolates, respectively. Published data indicated that in Iran, there has been an obvious predominance of these virus genetic patterns<sup>[10-13]</sup>. Other unpublished data (from personal communications) indicates that the genotype D is the only genotype of hepatitis B circulating in this country. Therefore, according to epidemiological studies so far, Iran is the only region in the world which harbored the unique pattern of HBV genotypic pattern.

According to archaeological and anthropological findings, the ancestors of Caucasians (Arians) firstly colonized to the North of the Caspian Sea. Because of difficulties in agriculture and climate change, they migrated in three directions thousand years ago: one group moved west towards Europe, another group moved south to Iran (and established the ancient Persian Empire) and the last group migrated to India. It might be that those people, who acquired the virus with the genotype D before their migration [perhaps related to immune pressure based largely on human leukocyte antigens (HLA) types], then transmitted the virus generation by generation after their migration. This hypothesis is underscored by the findings that the dominant Caucasians HBV genotype in India, Iran and most part of the Europe is D (Figure 1). After colonization of infected people, certain genotypes importation (especially B and C) to this area arose from miscegenation of people. Further evolution occurred, giving some of these sequences a distinctive motif, and some genetic recombination between genotypes also occurred, which led to the heterogenous pattern like India, Pakistan<sup>[14]</sup>. In some areas, isolation of people in the absence of intermixing with other genotypes led to a homologous pattern (like Iran and Turkey)<sup>[14]</sup>. Thus, the unique pattern of genotypic homogeneity in Iran reflects a founder event, in which, a new population is founded by a small number of incoming individuals, (similar to inter-house bottleneck in transmission), severely reduces genetic diversity, leading to homogeneity. The latter finding indicates a unique homogeneity belonged to the Iranian population.

The ratio between silent and missense nucleotide mutations (*dN/dS*) in our patients was 0.91 indicating that the proportion of deduced amino acid changes in these chronically infected patients followed a negative selection pattern. A conclusive assumption needed by comparing the whole HBV genome sequences, however, according to the average amino acid substitution and nucleotide frequency, we hypothesize that the evolution of HBV surface protein between Iranian patients is somehow low. Based on current investigations on genotype D of HBV, new findings show that HBV genotype D is able to cause severe diseases and higher rate of drug resistance in comparison to other studied genotypes. Thakur *et al*<sup>[25]</sup> reported

**Table 2** Pattern of nucleotide/amino acid distributions within the surface protein in correlation with HBeAg/anti-HBe status of the patients.

HBeAg Substitution levels	HBeAg Positive (n=73) 23.39%	Anti-HBe Positive (n=221) 70.83%	P-Value
Nucleotide mutation	65	200	0.82
Nucleotide Silent Mutations (n=85)	31	49	0.001
Amino Acid Mutation	36	162	<0.001
“a” determinant Mutations (n=34)	7	27	0.67
No nucleotide and amino acid Mutations (n=22)	7	12	0.27

that genotype D of HBV correlates with more severe liver disease than HBV genotype A in India, especially in young HBV infected patients may be lead to HCC. Other report comparing the clinical outcome of chronic HBV infection between different genotypes indicating the worst complications caused by genotype D<sup>[26,27]</sup>. We were not being able to compare our group of patients with genotype D with the other groups of HBV genotypes. However, according to the epidemiologic studies, the prevalence of cirrhosis and HCC, the major complications of chronic HBV infection in Iran (including these regions-studied) are relatively low<sup>[28,29]</sup> and HCC is not included in the list of top ten cancers in Iranian population (regardless of role of HBV as an etiology)<sup>[30-32]</sup>. In chronic carriers, the transition from a relative immune tolerance state (HBeAg positivity) to the activation of the immune system with generation of anti-HBe results in a strong selection on the viral genome, causing changes in immune targets (HBsAg). This seroconversion reflects the evolution of the accumulated mutations as time goes by according to molecular clock. Although the impact of such mutations in the pathogenesis of cirrhosis and HCC is not clear, the rough conclusion is that due to this negative selection and the uniqueness pattern of HBV genotype in this ethnic group, these complications are lower than other published studies so far<sup>[16]</sup>. A definite conclusion needs mutational analysis of sequential samples from different stages of chronically-infected individuals in cohort groups of different genotypes.

In conclusion, the unique pattern of HBV genetics homogeneity together with the low mutational frequency indicated that HBV was introduced to Iran recently and isolation of people in the absence of intermixing with other genotypes led to a homologous pattern. This uniqueness deserves more epidemiological and biomolecular studies with regard to other genotypes to explore the biological impacts of different strains on the complications of HBV infection.

## ACKNOWLEDGMENTS


This study was supported by Tehran University of Medical Sciences (Grant No: 860227-5816). We are deeply indebted to Dr Helen Norder and Professor Lars Magnus for technical assistance of phylogenetic tree designing.

## CONFLICT OF INTERESTS

There are no conflicts of interest with regard to the present study.

## REFERENCES

- Hepatitis., W.H.A.V., Global Policy. [www.worldhepatitisalliance.org/.../Viral\\_Hepatitis\\_Global\\_Policy.sfb.ashx](http://www.worldhepatitisalliance.org/.../Viral_Hepatitis_Global_Policy.sfb.ashx), 2010.
- Carman WF, Tomas H, Zuckerman AJ, Harrison TJ. Molecular variants. 1998, Hong Kong: Churchill Livingstone
- Arauz-Ruiz P, Norder H, Robertson BH, Magnus LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. *J Gen Virol* 2002; **83**(Pt 8): p. 2059-73
- Naumann H, Schaefer S, Yoshida CF, Gaspar AM, Repp R, Gerlich WH. Identification of a new hepatitis B virus (HBV) genotype from Brazil that expresses HBV surface antigen subtype adw4. *J Gen Virol* 1993; **74** ( Pt 8): p. 1627-32
- Norder H, Couroucé AM, Magnus LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. *Virology* 1994; **198**(2): p. 489-503
- Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. *J Gen Virol* 2000; **81**(Pt 1): p. 67-74.
- Okamoto H, Imai M, Kametani M, Nakamura T, Mayumi M. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through maternal-fetal transmission. *Jpn J Exp Med* 1987; **57**(4): p. 231-6
- Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnus LO. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. *Intervirology* 2004; **47**(6): p. 289-309
- Kidd-Ljunggren K, Broman E, Ekvall H, Gustavsson O. Nosocomial transmission of hepatitis B virus infection through multiple-dose vials. *J Hosp Infect* 1999; **43**(1): p. 57-62.
- Mohebbi SR, Amini-Bavil-Olyae S, Zali N, Derakhshan F, Sabahi F, Zali MR. An Extremely Aberrant Subtype of Hepatitis B Virus Genotype D in Iran. *Hepat Mon* 2009; **9**(1): p. 73-75
- Kohshour MO, Galehdari H, Foroughmand AM, Andashti B, Jalalifar MA, Bidmeshkipour A. HBV Genotyping in HBsAg-Positive Blood Donors from Southwestern Iran. *Hepat Mon* 2010; **10**(2): p. 147-148
- Taghavi SA, Tabibi M, Eshraghian A, Keyvani H, Eshraghian H. Prevalence and Clinical Significance of Hepatitis B Basal Core Promoter and Precore Gene Mutations in Southern Iranian Patients. *Hepat Mon* 2010; **10**(4): p. 294-297
- Vaezjalali M, Alavian SM, Jazayeri SM, Nategh R, Mahmoodi M, Hajibeigi B, Mokhtari Azad T. Genotype of Hepatitis B Virus Isolates from Iranian Chronic Carriers of the Virus. *Hepat Mon* 2008; **8**(2): p. 97-1100
- Jazayeri SM, Carman WF. Evolution of hepatitis B genotype D in the Middle east and South Asia. *Hep Mon* 2009; **9**(1): p. 3
- Ghaziasadi A, Ziaee M, Norouzi M, Malekzadeh R, Alavian SM, Saberfar E, Judaki MA, Ghamari S, Khedive A, Namazi A, Rahimnia R, Jazayeri SM. The Prevalence of Hepatitis B Virus Surface Antigen (HBsAg) Variations and Correlation with the Clinical and Serologic Pictures in Chronic Carriers from Khorasan Province, North-East of Iran. *Acta Med Iran* 2012; **50**(4): p. 265-72
- Khedive A, Sanei-Moghaddam I, Alavian SM, Saberfar E, Norouzi M, Judaki M, Ghamari S, Jazayeri SM. Hepatitis B Virus Surface Antigen (HBsAg) Mutations Are Rare but Clustered in Immune Epitopes in Chronic Carriers from Sistan-Balouchestan Province, Iran. *Arch Iran Med* 2013; **16**(7): p. 385-9
- Norouzi M, Ghorashi S, Abedi F, Nejatizadeh A, Ataei B, Malekzadeh R, Alavian S, Judaki M, Ghamari S, Namazi A, Rahimnia R, Khedive A, Jazayeri S. Identification of Hepatitis B Virus Surface Antigen (HBsAg) Genotypes and Variations in Chronic Carriers from Isfahan Province, Iran. *Iran J Public Health* 2012; **41**(3): p. 104-11
- Sayad B, Anvari FA, Alavian SM, Norouzi M, Hamzelooc M, Shirvani M, Pourhoseingholi A, Khedive A, Ghamari S, Judaki MA, Jazayeri SM. Correlation of Hepatitis B surface antigen mutations with clinical status of the chronically infected patients from Kermanshah, West of Iran. *Minerva Gastroenterol Dietol* 2012; **58**(1): p. 9-18
- Ramezani F, Norouzi M, Sarizade GR, Poortahmasebi V, Kalantar E, Magnus L, Norder H, Domingo E, Jazayeri SM. Mutation hot spots in hepatitis B surface antigen in chronic carriers from khoozestan province, southern of iran. *Iran J Allergy Asthma Immunol* 2013; **12**(3): p. 269-75
- Norouzi M, Ghorashi SA, Ataei B, Yaran M, Malekzadeh R, Alavian SM, Judaki MA, Ghamari S, Namazi A, Rahimnia R, Khedive A, Jazayeri SM. Hepatitis B Virus Surface Antigen Variants Clustered Within Immune Epitopes in Chronic Hepatitis B Carriers from Hormozgan Province, South of Iran. *Iranian Journal of Basic Medical Sciences* 2010; **13**(4): p. 12
- Jazayeri SM, Basuni AA, Sran N, Gish R, Cooksley G, Locarnini S, Carman WF. HBV core sequence: definition of genotype-specific variability and correlation with geographical origin. *J Viral Hepat* 2004; **11**(6): p. 488-501



Norouzi M *et al.* Exclusive distribution of HBV genotype D in Iran

- 22 Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. *Mol Biol Evol* 2007; **24**(8): p. 1596-9
- 23 Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, Mayumi M. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. *J Gen Virol* 1988; **69** (Pt 10): p. 2575-83
- 24 Khedive A, Norouzi M, Ramezani F, Karimzadeh H, Alavian SM, Malekzadeh R, Montazeri G, Nejatizadeh A, Ziaee M, Abedi F, Ataci B, Yaran M, Sayad B, Somi MH, Sarizadeh G, Sanei-Moghaddam I, Mansour-Ghanaei F, Rafatpanah H, Pourhosseingholi MA, Keyvani H, Kalantari E, Saberifiroozi M, Judaki MA, Ghamari S, Daram M, Mahabadi M, Fazeli Z, Goodarzi Z, Poortahmasebi V, Jazayeri SM. Hepatitis B virus surface protein mutations clustered mainly in CTL immune epitopes in chronic carriers: results of an Iranian nationwide study. *J Viral Hepat* 2013; **20**(7): p. 494-501
- 25 Thakur V, Guptan RC, Malhotra V, Basir SF, Sarin SK. Prevalence of hepatitis B infection within family contacts of chronic liver disease patients--does HBcAg positivity really matter? *J Assoc Physicians India* 2002; **50**: p. 1386-94
- 26 Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. *Semin Liver Dis* 2013; **33**(2): p. 97-102
- 27 Shi YH. Correlation between hepatitis B virus genotypes and clinical outcomes. *Jpn J Infect Dis* 2012; **65**(6): p. 476-82
- 28 Alavian SM. Hepatitis B virus infection in Iran; Changing the epidemiology. *Iranian Journal of Clinical Infectious Diseases* 2010; **5**(1): 51-61
- 29 Veazjalali M, Norder H, Magnus L, Jazayeri SM, Alavian SM, Mokhtari-Azad T. A new core promoter mutation and premature stop codon in the S gene in HBV strains from Iranian patients with cirrhosis. *J Viral Hepat* 2009; **16**(4): p. 259-64
- 30 Mohagheghi MA, Alireza Mosavi-Jarrahi, Reza Malekzadeh, Max Parkin. Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998-2001. *Arch Iran Med* 2009; **12**(1): p. 15-23
- 31 Sadjadi A, Reza Malekzadeh, Mohammad H Derakhshan, Alireza Sepehr, Mehdi Nouraie, Masoud Sotoudeh, Abbas Yazdanbod, Behrooz Shokoohi, Afshin Mashayekhi, Shahnaz Arshi, Ali Majidpour, Masoud Babaci, Alireza Mosavi, Mosavi Mohammad Ali Mohagheghi, Masomeh Alimohammadian. Cancer occurrence in Ardabil: results of a population-based cancer registry from Iran. *Int J Cancer* 2003; **107**(1): p. 113-8
- 32 Semnani S, Alireza Sadjadi, Saman Fahimi, Mehdi Nouraie, Mohamad Nacimi, Javad Kabir, Hafez Fakheri, Hasan Saadatnia, Mohamad Reza Ghavamnasiri, Reza Malekzadeh. Declining incidence of esophageal cancer in the Turkmen Plain, eastern part of the Caspian Littoral of Iran: a retrospective cancer surveillance. *Cancer Detect Prev* 2006; **30**(1): p. 14-9
- Peer reviewer:** Mohammad Khalid Pravez, PhD, Department of Pharmacognosy, King Saud University College of Pharmacy, Riyadh 11541, Saudi Arabia.

